0001493152-19-010238.txt : 20190703 0001493152-19-010238.hdr.sgml : 20190703 20190703130136 ACCESSION NUMBER: 0001493152-19-010238 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190703 DATE AS OF CHANGE: 20190703 EFFECTIVENESS DATE: 20190703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Luckwel Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001567098 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461660653 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-187874 FILM NUMBER: 19940831 BUSINESS ADDRESS: STREET 1: 303 WYMAN STREET STREET 2: SUITE 300 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 1(781)728 0007 MAIL ADDRESS: STREET 1: 303 WYMAN STREET STREET 2: SUITE 300 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Luckycom Pharmaceuticals Inc. DATE OF NAME CHANGE: 20170419 FORMER COMPANY: FORMER CONFORMED NAME: LUCKYCOM INC DATE OF NAME CHANGE: 20130115 NT 10-K 1 nt10-k.htm

 

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

(Check One):

 

[X] Form 10-K [  ] Form 20-F [  ] Form 11-K [  ] Form 10-Q
       
[  ] Form 10-D [  ] Form N-SAR [  ] Form N-CSR  

 

For Period Ended: March 31, 2019

 

[  ] Transition Report on Form 10-K

 

[  ] Transition Report on Form 20-F

 

[  ] Transition Report on Form 11-K

 

[  ] Transition Report on Form 10-Q

 

[  ] Transition Report on Form N-SAR

 

For the Transition Period Ended:

 

Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

 

PART I

 

REGISTRANT INFORMATION

 

Full Name of Registrant LUCKWEL PHARMACEUTICALS INC.
   
Former Name if Applicable

LUCKYCOM PHARMACEUTICALS INC.

   
Address of Principal Executive  
   
Offices (Street and Number) 303 Wyman St Suite 300
   
City, State and Zip Code Waltham, MA 02451

 

 

 

 
 

 

PART II

 

RULE 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check appropriate box)

 

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III

 

NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed.)

 

The Company has encountered a delay in assembling the information, in particular its financial statements for the year ended March 31, 2019, required to be included in its March 31, 2019 Form 10-K Annual Report. The Company expects to file its March 31, 2019 Form 10-K Annual Report with the U.S. Securities and Exchange Commission within 15 calendar days of the prescribed due date.

 

PART IV

 

OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Kingrich Lee   (781)   728-0007
(Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

[X] Yes [  ] No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[  ] Yes [X] No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
 

 

LUCKWEL PHARMACEUTICALS INC.

(Name of Registrant as specified in charter)

 

Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

  By: /s/ Kingrich Lee
Date: July 3, 2019   Chief Financial Officer